Human CD109 Antibody Summary
Val22-Ser1268 (Tyr703Ser, Thr1241Met)
Accession # Q6YHK3
Complete Your Research
Complete Your Experiment
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of Human CD109 by Western Blot. Western blot shows lysates of U‑87 MG human glioblastoma/astrocytoma cell line. PVDF membrane was probed with 0.5 µg/mL of Sheep Anti-Human CD109 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4385) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (HAF016). A specific band was detected for CD109 at approximately 161 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.
Detection of CD109 in A431 Human Cell Line by Flow Cytometry. A431 human epithelial carcinoma cell line was stained with Human CD109 Antigen Affinity‑purified Polyclonal Antibody (Catalog # AF4385, filled histogram) or isotype control antibody (Catalog # 5-001-A, open histogram), followed by NorthernLights™ 557-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # NL010).
CD109 in Human Squamous Cell Carcinoma. CD109 was detected in immersion fixed paraffin-embedded sections of human squamous cell carcinoma using 15 µg/mL Sheep Anti-Human CD109 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4385) overnight at 4 °C. Tissue was stained with the Anti-Sheep HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS019) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Detection of Human CD109 by Simple WesternTM. Simple Western lane view shows lysates of U‑87 MG human glioblastoma/astrocytoma cell line, loaded at 0.2 mg/mL. A specific band was detected for CD109 at approximately 161 kDa (as indicated) using 20 µg/mL of Sheep Anti-Human CD109 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4385). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
CD109 is a GPI-anchored member of the alpha-2-macroglobulin (A2M) and complement family of proteins (1). Mature human CD109 contains a bait region with recognition sequences for multiple proteases, an internal thioester bond, and a domain similar to the receptor binding domain of A2M (2). Cleavage of A2M family proteins within the bait region activates the thioester bond to promote covalent bonding to nucleophilic groups in adjacent molecules (3, 4). Within the region included in this recombinant protein, human CD109 shares 71-73% amino acid (aa) sequence identity with mouse and rat CD109. It shares 27-33% aa sequence identity with A2M and complement factors C3, C4, and C5. Alternate splicing of human CD109 generates two isoforms with short deletions and one that is truncated within the bait region. CD109 is expressed on activated T cells and platelets, hematopoietic stem cells, megakaryocyte precursors, vascular endothelial cells, basal and myoepithelial cells of secretory glands, and squamous cell carcinomas (2, 5-9). It is produced as a 170-180 kDa glycoprotein that is autocatalytically processed to 150 kDa and 120 kDa forms (2, 6, 10). CD109 on keratinocytes binds TGF-beta and associates with TGF-beta RI and TGF-beta RII, resulting in inhibition of TGF-beta signaling (11). Polymorphisms of CD109 include the platelet-specific Gov antigen and the blood group ABH antigens (12, 13). Alloantibodies directed against these antigens result in unsuccessful platelet transfusions, neonatal alloimmune thrombocytopenia, and posttransfusion purpura (14).
- Travis, J. and G.S. Salvesen (1983) Annu. Rev. Biochem. 52:655.
- Lin, M. et al. (2002) Blood 99:1683.
- Christensen, U. and L. Sottrup-Jensen (1984) Biochemistry 23:6619.
- Wallis, R. et al. (2007) J. Biol. Chem. 282:7844.
- Murray, L.J. et al. (1999) Exp. Hematol. 27:1282.
- Haregewoin, A. et al. (1994) Cell. Immunol. 156:357.
- Hasegawa, M. et al. (2007) Pathol. Int. 57:245.
- Brashem-Stein, C. et al. (1988) J. Immunol. 140:2330.
- Hashimoto, M. et al. (2004) Oncogene 23:3716.
- Solomon, K.R. et al. (2004) Gene 327:171.
- Finnson, K.W. et al. (2006) FASEB J. 20:1525.
- Schuh, A.C. et al. (2002) Blood 99:1692.
- Kelton, J.G. et al. (1998) J. Lab. Clin. Med. 132:142.
- Rozman, P. (2002) Transpl. Immunol. 10:165.
Citation for Human CD109 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity
Authors: P Filppu, JT Ramanathan, KJ Granberg, E Gucciardo, H Haapasalo, K Lehti, M Nykter, V Le Joncour, P Laakkonen
JCI Insight, 2021;6(9):.
Sample Types: Cell Lysates
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human CD109 Antibody
Average Rating: 4 (Based on 1 Review)
Have you used Human CD109 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image